A cross-party bill seeking to lift the French ban on preimplantation genetic testing for aneuploidies will be debated in the National Assembly on December 1, 2026, following an announcement by lawmakers on Tuesday.
The legislation aims to integrate embryo chromosome screening into standard medically assisted reproduction procedures.
- What PGD-A is: Preimplantation genetic testing for aneuploidies (PGD-A) checks an in vitro fertilization embryo for the correct number of chromosomes before uterine transfer.
- The clinical target: It screens for chromosomal abnormalities, which are a primary biological driver of implantation failure, early pregnancy loss, and abnormal development.
The legislative push stems directly from a parliamentary report addressing declining national birth rates.
“C’est avant tout une avancée majeure pour la santé des femmes,” Constance de Pélichy told magicmaman.
According to figures cited by de Pélichy, more than 65,000 embryo transfers in France fail to result in a live birth every year, accounting for roughly three out of every four attempts.
The proposed legislative change has drawn backing from high-profile figures across the political spectrum. Health Minister Stéphanie Rist has expressed support for the measure.
Green presidential candidate Marine Tondelier has also endorsed the initiative, having previously traveled abroad for the procedure prior to the birth of her son Léon.
| Clinical Parameter | Standard IVF (Without PGD-A) | Assisted Reproductive Technology with PGD-A |
|---|---|---|
| Primary Screening Target | Morphological assessment under light microscopy | Numerical chromosomal copy number analysis |
| Transfer Decision Basis | Visual cellular grading | Euploid status confirmation |
| Regulatory Status in France | Fully authorized and practiced | Currently prohibited (Pending Dec 1 review) |
PGD-A is not indicated for every patient demographic, and individual prognosis depends heavily on maternal age, ovarian reserve, and underlying male or female factor infertility. Individuals experiencing recurrent implantation failure or consecutive miscarriages should consult a reproductive endocrinologist to review diagnostic options tailored to their specific medical history.
The National Assembly will debate the transpartisan bill in public session on December 1, 2026.
- magicmaman reporting on the PGD-A legislative proposal announced on November 10, 2026.
- French National Assembly legislative agenda on assisted reproduction technologies.
